Close

Serbia gets shipment of AstraZeneca COVID-19 vaccine made in India

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

A shipment of 150,000 COVID-19 vaccines developed by AstraZeneca and Oxford University arrived at Belgrade airport on Sunday, making Serbia the first country in the Western Balkan region to receive supplies of the shot.

The vaccines, which arrived on a Turkish Airlines plane from Istanbul, were produced in India, said President Aleksandar Vucic, who came to the airport to meet the shipment.

Vucic said the price of the vaccine was “very good as both AstraZeneca and Oxford gave up their profits”. He added that another shipment of 150,000 vaccines is expected in 12 weeks time.

“This vaccine was developed by a young team at the Oxford University which also included young people from Serbia,” British ambassador Sian MacLeod told reporters at the airport.

More than 730,000 people, or a little over 10 per cent of the population, have been vaccinated against COVID-19 since December with one or two doses of the vaccines available in Serbia.

Under the state vaccination programme, Serbians have been able to choose between shots from Pfizer-BioNTech , China’s Sinopharm or Russia’s Sputnik V.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back